Chengdu Bio-town Fund
No. 868, Huoyun Road, Chengdu, Sichuan, 610200, China
Overview
Chengdu International Bio-Town Investment and Development co., Ltd. is a joint venture established by Chengdu Hi-Tech Industrial Development Zone and Shuangliu District, was founded on May 10, 2016 with the registered capital of CNY 1.5 billion. It’s responsible for the infrastructure construction, supporting construction, industrial investment, and operation of the 44 km² Chengdu Tianfu International Bio-Town.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
Investment portfolio
- Siyi Intelligence
Led · Series A · Mar 2023
SiYi Intelligence designs, develops and commercializes intelligent rehabilitation products for clinical and home/community use, including the SYREBO® soft robotic hand rehabilitation glove, EasyWalk exoskeleton, EEG-based assistive BCIs, and transcutaneous electrical nerve stimulation devices and accessories. The company plans to use funding to accelerate R&D of integration solutions for neurorehabilitation and to build a digital rehabilitation service platform. SiYi has marketed products in over 80 countries and regions and serves about 3,000 clinics and 50,000 households. Founded in 2017 and led by CEO Gavin Yin, the company has carried out collaborations with institutions such as Shanghai Jiao Tong University, Tohoku University, the Royal Buckinghamshire Hospital, Manus Brescia Rehabilitation Center, and Hongkong ShaTin Hospital. By 2022 the company held over 30 authorized patents, more than 50 registered trademarks, and over 10 software copyrights. It completed nearly USD15M in Series A financing to support its product and platform development.
- Ucello Therapeutics
Participated · Series A · Feb 2022
Ucello Therapeutics is a biotechnology company based in San Diego, CA and Chengdu, China focused on developing universal (allogeneic) CAR-T therapies. The company is powered by its proprietary universal CAR-T cell technology platform, CBT-X20. Ucello has developed several off-the-shelf cell therapy pipelines targeting solid tumors and hematologic malignancies, with lead asset AT19. The company plans to use recent funding to advance CBT-X20, progress pipeline programs including AT19 toward US and China IND filings, and build state-of-the-art GMP-ready clinical manufacturing facilities. Ucello is led by CEO Dr. Qiang Zou. It recently closed a Series A financing to support these development and manufacturing objectives.
Team
No current team members are available.